Immatics N.V. (IMTX) stock experienced a decline on Thursday following the announcement of a $150 million public offering. However, the company also shared promising Phase 1b data for its IMA203 TCR-T therapy targeting PRAME in melanoma patients, indicating potential for a significant breakthrough in the treatment of this aggressive cancer.